Abstract
In view of the calcium hypothesis the effect of nimodipine (Bay e 9736, CAS 66085-59-4) on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced depletions in dopamine and serotonin were investigated in C57-BL/6 mice. Oral treatment with nimodipine (5 mg/kg and 20 mg/kg b.i.d., respectively, for 9 days) prior to, during and following administration of MPTP appeared to attenuate MPTP-induced neurochemical changes in a dose-related manner. The results suggest that nimodipine reduces MPTP-induced damages, especially in the serotoninergic system, through its calcium antagonistic effects.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / analogs & derivatives*
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
-
3,4-Dihydroxyphenylacetic Acid / metabolism
-
Animals
-
Biogenic Amines / metabolism*
-
Caudate Nucleus / drug effects
-
Caudate Nucleus / metabolism*
-
Dopamine / metabolism
-
Dopamine Agents / pharmacology*
-
Homovanillic Acid / metabolism
-
Hydroxyindoleacetic Acid / metabolism
-
Mice
-
Mice, Inbred C57BL
-
Nimodipine / pharmacology*
-
Serotonin / metabolism
Substances
-
Biogenic Amines
-
Dopamine Agents
-
3,4-Dihydroxyphenylacetic Acid
-
1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine
-
Serotonin
-
Hydroxyindoleacetic Acid
-
Nimodipine
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Dopamine
-
Homovanillic Acid